Histogen (FRA:CPH) ROCE % : -182.92% (As of Sep. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Histogen ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Histogen's annualized ROCE % for the quarter that ended in Sep. 2023 was -182.92%.

Histogen ROCE % Historical Data

The historical data trend for Histogen's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Histogen ROCE % Chart

Histogen Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

ROCE %

-68.47

-269.09

-82.70

-51.67

Histogen Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
ROCE %	Get a 7-Day Free Trial													-72.99	-59.24	-84.89	-60.82	-182.92

Histogen ROCE % Calculation

Histogen's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	-10.047	/	( ( (24.112 - 2.062)	+	(18.005 - 1.165) )	/ 2 )
	=	-10.047	/	( (22.05	+	16.84)	/ 2 )
	=	-10.047	/	19.445
	=	-51.67 %

Histogen's ROCE % of for the quarter that ended in Sep. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2023 )		(Q: Jun. 2023 )		(Q: Sep. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2023 )		(Q: Jun. 2023 )		(Q: Sep. 2023 )
	=	-14.444	/	( ( (12.499 - 0.894)	+	(5.451 - 1.263) )	/ 2 )
	=	-14.444	/	( ( 11.605	+	4.188 )	/ 2 )
	=	-14.444	/	7.8965
	=	-182.92 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

Histogen (FRA:CPH) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Histogen ROCE % Related Terms

Thank you for viewing the detailed overview of Histogen's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Histogen (FRA:CPH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Histogen Inc (FRA:CPH) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

HSTO:USA

Address

10655 Sorrento Valley Road, Suite 200, San Diego, CA, USA, 92121

Website

https://www.histogen.com

Histogen Inc is a clinical-stage therapeutics company focused on developing proprietary hypoxia-generated growth factor technology platforms and stem cell-free biologic products as potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function. Under its biologics technology platform, the product candidates in development are HST-003, a treatment for joint cartilage repair, and HST-004, a treatment for spinal disc repair. It also has a pipeline of clinical and preclinical small molecule pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases that the company intends to develop.

Histogen (FRA:CPH) Headlines

No Headlines